ArticleFuture science OA2025
Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the efficacy of immune checkpoint inhibitors (ICIs) combined with chemoradiotherapy and evaluate the prognostic value of peripheral inflammatory markers in elderly patients with inoperable esophageal squamous cell carcinoma (ESCC).
methodsA retrospective study of 124 elderly ESCC patients treated between 2021 and 2024. Patients were divided into immunotherapy and non-immunotherapy groups. Progression-free survival (PFS) was compared, and inflammatory markers were analyzed using Cox regression and ROC curves.
resultsMedian PFS was significantly longer in the ICI group (13.7 vs. 10.9 months, P = 0.043). Immunotherapy was an independent protective factor for PFS. Post-treatment NLR and PNI were predictive of outcomes in the ICI group.
conclusionCombining ICIs with chemoradiotherapy improves survival in elderly inoperable ESCC patients. NLR and PNI may serve as accessible biomarkers to guide immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.